Altimmune, Inc. (ALT)
$14.03
+0.12 (+0.86%)
Rating:
Recommendation:
Neutral
| Symbol | ALT |
|---|---|
| Price | $14.03 |
| Beta | 0.190 |
| Volume Avg. | 1.42M |
| Market Cap | 689.702M |
| Shares () | - |
| 52 Week Range | 3.83-23.49 |
| 1y Target Est | - |
| DCF Unlevered | ALT DCF -> | |
|---|---|---|
| DCF Levered | ALT LDCF -> | |
| ROE | 5.13% | Neutral |
| ROA | 4.46% | Neutral |
| Operating Margin | - | |
| Debt / Equity | 9.88% | Neutral |
| P/E | - | |
| P/B | 3.37 | Strong Buy |
Latest ALT news
About
Download (Excel)Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.